First step: testing new drug in people with liver problems
NCT ID NCT05582187
Summary
This early-stage study aimed to understand how a single dose of the experimental drug fosmanogepix is processed by the body in people with different levels of liver function. It involved 28 adults, some with healthy livers and some with mild to severe liver impairment. The main goal was to measure drug levels in the blood and check for safety to guide future dosing in patients with liver conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Genesis Clinical Research, LLC
Tampa, Florida, 33603, United States
-
Inland Empire Liver Foundation
Rialto, California, 92337, United States
Conditions
Explore the condition pages connected to this study.